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ABSTRACT 
Objective: This study aimed to examine the safety of 5-aminolevulinic acid phosphate (5-ALA) 
with  sodium  ferrous  citrate  (SFC)  in  diabetic  patients  treated  with  one  or  more  oral 
hypoglycemic agents (OHAs). 
 
Background: Recent intervention studies performed in the USA and Japan have shown that a 
nutritional  supplement  of  5-ALA  with  SFC  efficiently  reduced  blood  glucose  levels  in 
pre-diabetic population without any adverse events. Thus, it was anticipated that 5-ALA with 
SFC may potentially be taken as a beneficial supplement by diabetic patients who were being 
treated with OHA therapy. Nevertheless, it is important to examine its safety and efficacy in 
diabetic population. 
 
Methods:  This  study  was  a  prospective  single-blinded,  randomized,  placebo-controlled  and 
parallel-group comparison study. Medically treated diabetic patients between the ages of 30 and 
75 were recruited from the Tokyo metropolitan area of Japan and 45 subjects were selected after 
screening. These subjects were randomly assigned to three groups: daily intake of 15mg 5-ALA, 
50mg 5-ALA, and a placebo (n=15, respectively). The supplement or placebo was administered 
for 12 weeks followed by a four week washout period. The primary endpoint was safety and Functional Foods in Health and Disease 2014; 4(9):415-428                                    Page 416 of 428 
occurrence of hypoglycemic attack, while the secondary endpoint was changes of fasting blood 
glucose (FBG) and hemoglobin A1c (HbA1c). 
 
Results:  Adverse  events  related  to  5-ALA  with  SFC  were  not  observed  in  all  the  groups. 
Abnormalities in blood and urine tests were not observed either. Significant decrease in FBG 
was not detected in all the groups. However, there was a small but significant decrease in HbA1c 
at 4 and 8 week in the 15 mg 5-ALA group. Significant decrease in HbA1c was not observed in 
the 50 mg 5-ALA group, although a tendency to decrease after 4 weeks was apparent. 
 
Conclusion: 5-ALA with SFC is a safe and potentially beneficial supplement if taken by diabetic 
patients treated with OHAs. 
 
Trial registration: UMIN 000008038 
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INTRODUCTION: 
The number of diabetic patients, especially those with type II diabetes, has been expanding in 
Japan [1] as in other countries recently [2, 3]. The main causes of increase in type II diabetes are 
considered to be excessive calorie intake and shortage of exercise. Inadequate management of 
diabetes  leads  to  the  development  of  complications,  such  as  retinopathy,  nephropathy,  and 
neuropathy,  which  deteriorate  the  quality  of  life  and  shorten  life  expectancy.  Incidence  of 
diabetic complications can be reduced if appropriate treatments are performed by maintaining 
HbA1c  levels  below  7.0%  and  blood  glucose  levels  close  to  normal  [4].  However,  a  large 
number of diabetic patients, treated with OHAs or insulin injections with controls that do not 
satisfy these criteria, exist. 
Dietary supplements are widely used in Japan but since they are intended to be taken by 
healthy people for the maintenance and promotion of health, it is important that tests for safety 
are  performed  on  healthy  and  borderline  subjects.  Next,  if  dietary  supplements  are  to  be 
administered  to  medically  treated  patients,  safety  tests  are  imperative  as  otherwise  there  is 
possibility that that it would worsen the disease. However it appears that the issue of safety with 
dietary supplement has not been attended properly as adverse events with the use of dietary 
supplements have been frequently reported both in healthy people and disease patients [5-11]. Functional Foods in Health and Disease 2014; 4(9):415-428                                    Page 417 of 428 
Disease exacerbation caused by dietary supplements has become a growing concern in Japan, so 
it  is  critical  to  examine  the  safety  of  dietary  supplements  in  patients  in  addition  to  healthy 
subjects.     
It  has  recently  been  shown  that  a  dietary  supplement,  5-aminolevulinic  acid  phosphate 
(5-ALA)  with  sodium  ferrous  citrate  (SFC),  reduces  blood  glucose  level  in  pre-diabetic 
populations without adverse events in the USA and Japan [12, 13]. 5-ALA is a natural amino 
acid and it is a precursor of heme, a major compartment of hemoglobin and myoglobin. 5-ALA 
is  also  an  essential  constituent  of  cytochromes  and  thus,  it  is  important  for  cellular  energy 
production in mitochondria [14]. It has been shown that exogenously applied 5-ALA with SFC 
increases  the  activity  of  complex  IV  in  the  mitochondrial  electron  transport  chain  in 
experimental animals [14] and increases the basal metabolic rate and suppresses fat accumulation 
in rats [15]. These findings appear to be compatible with the blood glucose lowering effect of 
pre-diabetes  in  humans  [12,  13].  Therefore  if  diabetic  patients  take  5-ALA  supplement  in 
addition to OHAs or insulin, there might be a risk of reducing blood glucose to a level that 
triggers  hypoglycemia  (hypoglycemic  attack).  Since  5-ALA  is  readily  accessible  to  diabetic 
patients without a physician’s prescription, it is desirable to obtain the safety test data of 5-ALA 
in these patients. Based on this consideration the present study was performed. 
 
METHODS: 
Study design. This study was a prospective single-blinded, randomized, placebo-controlled and 
parallel-group comparison study. The study protocol was approved by the Institutional Review 
Board (IRB) of the Institute of Medical Science, University of Tokyo, Japan and registered to 
University Hospital Medical Information Network (UMIN) as UMIN000008038. 
Diabetic patients treated with one or more OHAs were recruited from the patient panel of 
TES Holdings Co. Ltd. by internet advertisement. Total number of the registered patients was 
about 1000 and 81 candidates applied to this study from Tokyo metropolitan area of Japan. 
OHAs included sulfonylurea, DPP-4 inhibitor, α-glucosidase inhibitor, metformin, pioglitazone, 
glinide and GLP-1 analogue. The inclusion criteria for the diabetic patients were: (1) between the 
ages of 30 and 75 from whom written consent was obtained, (2) treated with OHAs, (3) without 
hypoglycemic attack for 3 months before inclusion, and (4) whose diabetic medication not to be 
altered during the study period. The exclusion criteria for the diabetic patients were: (1) treated with 
insulin, (2) with porphyria, hemochromatosis or viral hepatitis, (3) pregnant or possibly pregnant, (4) 
photo-hypersensitive, (5) enrolled in another clinical trial, or had a history of enrollment in another Functional Foods in Health and Disease 2014; 4(9):415-428                                    Page 418 of 428 
trial in the past 3 months, (6) taking anti-convulsant, anti-arrhythmic agents or coronary vasodilators, 
(7) allergic to drugs or food, (8) severely anemic (hemoglobin (Hb) < 8 mg/dl), (9) uncontrolled 
dependent on alcohol, and (10) severely psychotic patients. Patients deemed inappropriate to this 
study were judged by the principal investigator.     
Primary endpoint of this study was safety and occurrence of hypoglycemic attack (defined 
by symptoms including abnormal sensation of hunger, anxiety, palpitation, sweating, and tremor, 
which could be improved by glucose ingestion). Secondary endpoint was the changes of FBG 
and  HbA1c.  The  study  period  was  from  July  2012  to  June  2013,  and  data  were  finally 
summarized  in  December  2013.  The  Data  and  Safety  Monitoring  Committee  approved  the 
results and the conclusion of this study in April 2014. 
 
Patient selection and study schedule. Eighty-one candidates applied to this study. Because the 
recommended dose of 5-ALA with SFC as a supplement is 15 mg/day in Japan, we have chosen 
this dose as a low dose and 50 mg/day as a high dose. After the screening examination, 45 patients 
were  selected  and  randomized  equally  to  one  of  the  three  study  groups  according  to  age,  sex, 
sulfonylurea, and HbA1c: (1) low dose 5-ALA with SFC (15 mg 5-ALA and 17.2 mg SFC daily); (2) 
high dose 5-ALA with SFC (50 mg 5-ALA and 57.4 mg SFC daily); and (3) control (placebo capsule 
with identical color and size). All participants provided signed, informed consent according to the 
Declaration of Helsinki before enrolling in the study. Study subjects were administered with test 
or placebo capsules, and follow-up examinations were carried out 4, 8, and 12 weeks after the 
baseline examination. At week 16, a follow-up examination was carried out. Every examination 
included a medical interview, physical examination, measurement of blood pressure, pulse rate 
and body weight, blood test, urinalysis, and a dietary survey. A daily diary was used to monitor 
adverse events.     
Blood and urine samples were obtained during a fasting state in the morning. Blood test 
consisted  of  blood  count  (WBC,  RBC,  Hb,  Ht,  MCV,  MCH,  MCHC,  platelet)  and  blood 
chemistry (total protein, albumin, BUN, creatinine, uric acid, AST, ALT, γ-GTP, ALP, LDH, 
CPK,  TG,  LDL-cholesterol,  HDL-cholesterol,  total  bilirubin,  Na,  K,  Cl,  Fe,  FBG,  HbA1c, 
glycosylated albumin, lactic acid, insulin and transferrin). Urinalysis included pH, urobilinogen, 
occult blood, bilirubin, ketone, glucose, protein, creatinine and 8-hydroxy-2’-deoxyguanosine 
(8-OHdG). 
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three groups were examined by Fisher’s exact test. Differences in blood glucose and HbA1c 
were examined by two way factorial analysis of variance. Differences in quantitative data of 
blood  count  and  chemistry  were  examined  by  two  way  factorial  analysis  of  variance,  and 
difference in qualitative data was examined by Fisher’s exact test. 
 
RESULTS: 
Characteristics of patients in the present study  are shown in Table 1.  Age and sex, and the 
baseline  body  weight,  BMI,  systolic  &  diastolic  blood  pressure,  and  heart  rate  were  not 
significantly different among three groups. The numbers of oral hypoglycemic agents were 2.13 
± 1.03 (mean ± SD) in the 15 mg 5-ALA group, 2.00 ± 1.00 in the 50 mg 5-ALA group, and 1.93 
± 0.91 in the control group. Content of oral hypoglycemic agents and the number of patients are 
shown in Table 1.     
 
Table 1. Baseline characteristics of three groups 
 
 
 
Combination  drugs  composed  of  two  OHAs  were  prescribed  to  two  patients.  Each 
component was counted as a single drug in Table 1. It appeared that the prescribed drugs were 
not biased among the three groups. Blood count, blood chemistry and urinalysis were neither 
   5-ALA 15 mg    5-ALA 50mg    placebo
mean SD mean SD mean SD
Age (years) 60.5 7.8 60.3 8.8 60.9 8.0
Sex
    Male 12 12 12
    Female 3 3 3
Body weght (kg) 66.63 9.63 65.89 11.01 68.51 12.13
BMI (kg/m2) 23.83 3.04 24.16 2.52 25.08 2.67
Systolic blood pressure (mmHg) 123.1 13.9 119.6 14.9 117.9 13.4
Diastolic blood pressure (mmHg) 77.3 9.2 75.1 5.9 73.2 9.1
Heart rate (/min) 75.3 11.3 75.7 11.1 74.3 14.8
Number of anti-diabetic drugs 2.13 1.09 2.00 1.00 1.93 0.91
  Content of drugs  no. of patients no. of patients no. of patients
     sulfonylurea 9 11 10
     DPP-4 inhibitor 10 7 9
    metformin 5 2 2
     α-glycosidase inhibitor 4 6 6
     piogiytazone 3 4 1
     glinide 1 0 0
     GLP-1 agonist 0 0 1Functional Foods in Health and Disease 2014; 4(9):415-428                                    Page 420 of 428 
significantly different among the groups. Representable data are shown in Table 2. Evaluation of 
the primary endpoint (safety and hypoglycemic attack) was performed on candidates who took 
5-ALA with SFC more than once, and that of the secondary endpoint was performed for those 
who completed the entire study. The primary endpoint could be assessed in all 45 subjects while 
the secondary endpoint could be assessed in 37 subjects. The numbers of dropout subjects were 
two in the 15 mg 5-ALA group, five in the 50 mg 5-ALA group, and one in the control group. 
The reasons for dropout were changes of oral hypoglycemic agents determined by the physician 
in charge, difficulty to continue visit for this study or occurrence of transient ischemic attack 
(TIA).     
 
    Table 2. Baseline laboratory data of three groups 
 
 
TIA occurred in one subject when he was on the train during the visit to our hospital.    TIA 
persisted for only a few minutes and his consciousness was fully recovered. It was the 29
th day 
after taking 15 mg 5-ALA with SFC. It was concluded that TIA was ascribed to atherosclerosis 
of the brain artery and not to the test supplement. However, this subject was excluded from the 
study as decided by the principle investigator. Seventeen days after the termination of the study, 
stomach bleeding occurred in another subject. He checked in the hospital and blood transfusion 
  5-ALA 15 mg (n=15)   5-ALA 50mg (n=15)   placebo (n=15)
mean SD mean SD mean SD
WBC 5973.3 1255.5 6266.7 1784.3 6326.7 1612.7
Hb 13.83 1.38 14.52 0.96 14.23 1.29
Plt 21.25 4.82 23.15 5.35 21.66 6.39
TP 7.29 0.40 7.30 0.30 7.30 0.37
Alb 4.41 0.20 4.43 0.26 4.52 0.28
BUN 15.2 3.7 14.2 4.0 15.1 5.0
creatinine 0.825 0.170 0.806 0.174 0.841 0.164
UA 5.70 1.18 5.35 1.12 5.50 1.50
AST 19.9 10.3 20.4 5.7 21.2 6.5
ALT 20.3 11.7 23.2 10.7 24.3 10.4
r-GTP 30.4 20.9 33.3 24.4 36.9 25.3
ALP 196.7 39.8 212.5 62.5 211.4 56.1
LDH 175.1 18.8 177.3 29.7 179.2 25.7
TG 133.2 73.3 125.1 91.8 127.6 76.1
LDL 115.3 28.8 115.0 37.1 118.1 30.9
HDL 49.5 8.3 53.5 16.7 53.7 11.7
Fe 95.6 31.0 113.5 31.9 109.3 32.0
fasting blood glucose 136.3 31.1 131.0 16.2 134.2 27.1
HbA1c 7.01 1.08 6.92 0.53 7.05 0.91
glycoalbumin 19.63 3.67 18.93 3.50 18.19 3.55
insulin 7.08 6.37 5.55 2.41 6.37 3.04
8-OHdG 12.92 5.64 15.18 7.53 11.79 8.90Functional Foods in Health and Disease 2014; 4(9):415-428                                    Page 421 of 428 
was carried out. After 6 days he was recovered and discharged. This event was categorized as a 
serious adverse event and it was reported to IRB. However, since this subject belonged to the 
control group this adverse event was not related to 5-ALA with SFC. No adverse events related 
to 5-ALA with SFC was observed in the test groups. Abnormalities in blood and urine tests were 
not observed.   
The secondary endpoint of this study was the change of FBG and HbA1c. It was evaluated 
in 13 subjects in the 15 mg 5-ALA group, 10 subjects in the 50 mg 5-ALA group, and 14 
subjects in the control group (the number of subjects is different between Table 1 and Table 3). 
Significant decrease in FBG was not detected in all groups but a small increase at week 12 in the 
50 mg 5-ALA group was observed (Table 3). A small but significant decrease in HbA1c was 
found at week 4 and 8 in the 15 mg 5-ALA group. Serum insulin levels appeared to decrease at 
week 4, 8, and 12 in the 15 mg 5-ALA group, but the change was not statistically significant. A 
significant decrease in HbA1c was not observed in the 50 mg 5-ALA group, although it showed 
a tendency to decrease after 4 weeks.   
 
Table 3. Changes of fasting blood glucose, HbA1c, and insulin 
 
         
Data are expressed as mean ± SD. 
Before  4 week  8 week  12 week  washout 
Fasting blood glucose (mg/dl) 
    5-ALA 15mg (n=13)  136.7±9.2  128.4±6.7  131.0±7.3  134.5±6.8  138.4±7.3 
    5-ALA 50 mg (n=10) 128.2±4.4  123.4±5.2  128.7±4.1  142.1±6.8* 135.5±8.0 
    placebo (n=14)  133.4±7.5  130.6±6.7  129.1±3.9  138.0±4.8  137.8±5.7 
* significant p < 0.05 as compared to before intake of 5-ALA 
Before  4 week  8 week  12 week  washout 
HbA1c (%) 
    5-ALA 15mg (n=13)  7.14±0.31  6.94±0.28* 6.89±0.23* 6.98±0.24  7.06±0.26 
    5-ALA 50 mg (n=10) 6.88±0.17  6.70±0.12  6.80±0.13  6.85±0.18  7.07±0.20 
    placebo (n=14)  7.09±0.25  7.03±0.20  6.98±0.20  7.05±0.17  7.15±0.20 
* significant p < 0.05 as compared to before intake of 5-ALA 
Before  4 week  8 week  12 week  washout 
Insulin 
    5-ALA 15mg (n=13)  5.41±3,32  4.43±1.89  4.78±2.45  4.38±2.17  5.45±2.60 
    5-ALA 50 mg (n=10) 5.89±2.28  5.59±1.83  4.76±2.18  5.57±2.40  4.99±1.75 
    placebo (n=14)  6.46±3.13    5.89±2.41  7.84±5.58  6.71±3.53  7.41±3.41 Functional Foods in Health and Disease 2014; 4(9):415-428                                    Page 422 of 428 
Figure. 1. Relationship between hemoglobin and HbA1c during study period. The ordinate (Hb) 
indicates  the  hemoglobin  concentration  and  the  abscissa  (HbA1c),  HbA1c  level.  Each  point 
corresponds to the data from one subject who completed the study. Some symbols overlapped 
each other among subjects. 
 
Since 5-ALA is a precursor of heme and SFC was included in the supplement, it was plausible to 
speculate that the intake of this supplement would have changed Hb, which, in turn, affected the 
HbA1c level. However, no significant changes of serum iron and Hb were observed during the 
study period among all the groups. We further analyzed the relationship between Hb and HbA1c, 
and  that  between  glycosylated  albumin  and  HbA1c.  As  shown  in  Figure  1,  there  was  little 
correlation  between  Hb  and  HbA1c.  On  the  contrary,  HbA1c  was  strongly  correlated  to 
glycosylated albumin, which is not affected by serum iron or Hb [16] (Figure 2). These results 
indicate that HbA1c correctly represented the changes of blood glucose level. Functional Foods in Health and Disease 2014; 4(9):415-428                                    Page 423 of 428 
Figure  2.  Relationship  between  glycosylated  albumin  and  HbA1C  during  study  period.  The 
ordinate (GA) indicates glycosylated albumin  level  and the  abscissa (HbA1c), HbA1c level.   
Each point corresponds to the data from one subject who completed the study. Some symbols 
overlapped each other among subjects 
 
DISCUSSION: 
The results of the present study showed that the supplemental use of 5-ALA with SFC appears to 
be safe for diabetic patients who are treated with OHAs. However the number of the subjects in 
this study is small, a larger scale study is necessary to draw a clear conclusion. In the Hawaii 
study (n=154), 5-ALA with SFC significantly reduced blood glucose level after a two h oral 
glucose  tolerant  test  (OGTT)  in  pre-diabetic  participants  [12].  The  effect  was  especially 
prominent among the subjects with baseline of two h OGTT levels greater than 140 mg/dl both 
in the 15 mg and 50 mg 5-ALA groups. In the Hiroshima study (n=212), 15 mg 5-ALA with 
SFC  significantly  reduced  all  of  the  fasting  glucose  level,  glycosylated  albumin,  and  blood 
glucose level after two h of OGTT in mildly hyperglycemic participants [13]. Thus, it has been 
demonstrated  that  5-ALA  with  SFC  improves  glucose  metabolism  in  pre-diabetic  subjects. Functional Foods in Health and Disease 2014; 4(9):415-428                                    Page 424 of 428 
5-ALA with SFC is a supplement available at drug stores without a doctor’s prescription and 
therefore it is probable that medically treated diabetic patients purchase this supplement, and take 
it in addition to prescribed drugs. In such occasion, the additional use of 5-ALA with SFC might 
lead  to  hypoglycemia  or  other  adverse  effects  in  diabetic  patients  who  are  under  medical 
treatment. Therefore, the purpose of our study was designated to examine the safety and the 
occurrence of hypoglycemic attack. Our study revealed adverse events were not triggered by 
5-ALA with SFC with absence of hypoglycemic attack in type II diabetes patients who were 
under medicinal treatment with OHAs.     
The HbA1c level, which was set as the secondary end point in this study, was significantly 
reduced at 4 and 8 weeks in the 15 mg 5-ALA group. Serum insulin did not increase at 4 or 8 
weeks but rather decreased during these periods, suggesting that 5-ALA improved the glucose 
metabolism via insulin-independent fashion. HbA1c showed a decrease in the 50 mg 5-ALA 
group but the change was not statistically significant. The average decrease in HbA1c by 5-ALA 
with SFC was less than 0.25% (range: 0.03-0.25%). It has been previously reported that the 
reduction of HbA1c was from 0.2 to 2% by metformin [17], 0.5 to 1.5% by sulfonylurea [17, 18], 
that by α-glucosidase inhibitor, up to 1% [17], that by DPP-4 inhibitors, 0.6 to 1% [19-22], and 
0.5 to 1.1% by GLP-1 analogue [22]. Furthermore a meta-analysis of the treatment of type II 
diabetes with dietary fiber has revealed that intervention by dietary fiber had an effect of HbA1c 
with  an  average decrease of 0.26%  [23], while another meta-analysis  of dietary  supplement 
cinnamon showed a 0.09 % decrease in mean HbA1c [24]. Taken together, the effect of 5-ALA 
with  SFC  on  HbA1c  in  diabetic  patients  appears  to  be  lower  than  those  by  OHAs  and 
comparable  to  dietary  supplements.  It  has  been  long  established  that  exercise  and  diet  are 
beneficial to diabetes mellitus. Exercise for more than 8 months significantly reduces HbA1c by 
0.66% without significant decrease of body weight [25]. Nutrition therapy was shown to be able 
to reduce HbA1c by 1 to 2% in type II diabetic patients [26, 27]. Thus, exercise and diet are very 
effective to control blood glucose level in diabetes. This observation was applicable even in the 
case in healthy people and pre-diabetic subjects.     
In the present study, the intake of 5-ALA with SFC did not alter serum iron concentration 
and Hb. Therefore, the decrease of HbA1c by 5-ALA with SFC was not ascribed to the change 
of Hb. It was apparent that there was a close relationship between HbA1c and glycosylated 
albumin as shown in this study, and therefore it was considered that HbA1c correctly reflected 
the change of blood glucose level. Although HbA1c significantly decreased after 4 and 8 weeks 
in the 15 mg 5-ALA group, no significant change was observed in glycosylated albumin. It was Functional Foods in Health and Disease 2014; 4(9):415-428                                    Page 425 of 428 
speculated that probably HbA1c is sensitive to blood glucose alteration more than glycosylated 
albumin. In the Hiroshima study, 5-ALA significantly decreased the glycosylated albumin in 
pre-diabetic  subjects,  but  no  significant  change  was  observed  in  HbA1c  [13].  The  authors 
discussed  that  glycosylated  albumin  reflects  the  rapid  change  of  blood  glucose  levels  as 
compared to HbA1c, and that glycosylated albumin reflects postprandial glucose change better 
than HbA1c, which is represented by the significant decrease of the glucose level at two h of 
OGTT [13]. In the Hawaii study, there was a tendency that 5-ALA with SFC decreased HbA1c 
in pre-diabetic subjects although it was not statistically significant (p=0.07) [12]. Glycosylated 
albumin also tended to decrease by 5-ALA with SFC, but similar to our study, it appeared that 
HbA1c was more sensitive than glycosylated albumin (p=0.22). However it is a premature state 
to at present to speculate the cause for the discrepancy of the relationship between HbA1c and 
glycosylated albumin among three studies. 
5-ALA with SFC has been shown to increase the metabolic rate in rats [15] and humans 
[Horiuchi et al. unpublished results]. It was anticipated that the application of 5-ALA with SFC 
would decrease body weight, but a significant decrease was not detected in either of the 5-ALA 
groups. Because the duration of the test period was 12 weeks, a longer application of 5-ALA 
might possibly exert some effect on body weight. It is also possible that body weight change may 
not be clearly detected in Japanese diabetic patients, because more than half of the diabetic 
patients are non-obese [28] as in other East Asian countries [29].   
In summary, 5-ALA with SFC can be safely taken by diabetic patients treated with OHAs. 
5-ALA  with  SFC  showed  some  activity  on  HbA1c  in  diabetic  patients,  but  the  symptoms 
ascribed to hypoglycemia were not observed. The number of applicants and test period were 
limited in this study, and a larger scale and longer follow-up study are deemed necessary to 
establish the safety of 5-ALA with SFC and its effect on glucose metabolism in diabetic patients.   
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